Fig. 6
From: A polymeric nanocarrier that eradicates breast cancer stem cells and delivers chemotherapeutic drugs
The in vivo tumor-targeted efficacy and BCSC-accessibility of HA-b-PCDA NPs. (A) In vivo fluorescence images of 4T1 tumor-bearing mice at different time points (0, 1, 2, 4, 8, 24 and 48 h) after administration of free Dir or Dir/HA-b-PCDA NPs. (B) Relative radiant fluorescence intensities of tumor areas in (A) at predetermined administration time points, n=3. (C) Ex vivo fluorescence images of the tumor and major organs at 48 h post-administration of free Dir or Dir/HA-b-PCDA NPs. a: Heart, b: Liver, c: Spleen, d: Lung, e: Kidney, f: Tumor. (D) Semi-quantification distribution of free Dir or Dir/HA-b-PCDA NPs in tumors and major organs at 48 h post-administration. (E) The permeation of free Dir or Dir/HA-b-PCDA NPs in the whole tumor mass, scale bar=5.0 mm. (F) Imaging analysis of the permeation of free Dir or Dir/HA-b-PCDA NPs by Image-Pro analyzer. (G) CLSM imaging of the access of free Dir or Dir/HA-b-PCDA NPs to the BCSCs in 4T1 tumors, scale bar=50 μm. (H, I) Imaging analysis of the BCSC-accessibility of free Dir (H) or Dir/HA-b-PCDA NPs (I) using Fiji (is just ImageJ) software. “*”, p<0.05; “**”, p<0.01